de Jong HMY, van Mens LJJ, Nurmohamed MT, et al. - Through an Open-label extension of a freshly published double-blind, randomized placebo-controlled trial, researchers examined whether remission induced by tumor necrosis factor-alpha inhibitor (TNFi) and methotrexate in patients with early psoriatic arthritis was maintained following the withdrawal of TNFi. In the extension phase, eight patients from the original placebo group and 18 patients from the original TNFi group proceeded. At week 50, six out of eight individuals from the original MTX (methotrexate) group vs ten out of 18 patients from the original MTX+TNFi group were in the Disease Activity Score (DAS)-CRP remission. Acknowledging the total study population, six out of 24 of the original MTX group in comparison with 10 out of 26 of the original MTX+TNFi group were in DAS remission at week 50. Thus, in early psoriatic arthritis, remission accomplished by initial combination treatment with TNFi and methotrexate is sustained on methotrexate monotherapy in nearly half of the patients.